Each week we highlight five things affecting the life sciences industry. Here’s the latest.
Manufacturing takes center stage in biopharma
- In 2024, biopharma companies prioritized manufacturing capabilities to attract investors and ensure scalability, as reported by BioSpace.
- Major companies are significantly investing in manufacturing infrastructure to support the production of popular drugs and prepare for future demands, while early-stage biotechs need to show how they can scale their product in the long run.
AI integrated in continuous glucose monitoring for personalized health insights
- Dexcom has introduced a generative artificial intelligence feature to its over-the-counter continuous glucose monitor, Stelo, enhancing personalized tips and recommendations for users regarding diet, exercise and sleep.
- This development aligns with the U.S. Food and Drug Administration’s ongoing exploration of generative AI in medical devices, with Dexcom collaborating with the agency to ensure compliance with emerging regulatory frameworks, per Medtech Dive.
Pharma R&D strategies for 2025: Focus on oncology and obesity
- In 2025, pharma companies are expected to prioritize research and development investments in oncology, obesity, immunology and neurology to offset losses from patent expirations and regulatory costs.
- The industry is also likely to see increased mergers and acquisitions activity to fill gaps in R&D, driven by economic conditions and the need for pipeline prioritization, according to PharmaVoice.
Advancing inclusivity in medical device development
- Virtual patient populations are being used to create more inclusive and efficient medical device development processes, ensuring that new devices meet the needs of diverse patient groups, Physics World reports.
- This approach leverages advanced modeling and simulation techniques to revolutionize how medical devices are tested and brought to market.
Pharmacy benefit managers and the opioid crisis
- According to The New York Times, pharmacy benefit managers (PBMs) are facing scrutiny for their role in the opioid crisis as they have been accused of prioritizing profits over patient safety by favoring more addictive medications.
- Lawmakers and regulators are pushing for reforms to hold PBMs accountable and ensure they contribute to safer prescribing practices.
Note: “5 things” will be pausing publication the weeks of Dec. 23 and 30. Look for our next issue the week of Jan. 6.
For more insights in life sciences, check out RSM’s industry outlook.
